Donna Berry on the Implications of Oral Oncolytics

Article

Donna Berry from the Phyllis F. Cantor Center at the Dana-Farber Cancer Institute on the Implications of Oral Oncolytics

Donna Berry, PhD, RN, AOCN®, FAAN, from the Phyllis F. Cantor Center at the Dana-Farber Cancer Institute on the implications of oral oncolytics as observed in her research on patient adherence to oral oncolytic therapy, symptom management, patient quality of life, and patient decision making in cancer treatment.

Recent Videos
5 experts in this video
5 experts in this video
Image of Jessie Desir, PhD, RN, AMB-BC, OCN, in a video call with a blue and gold Oncology Nursing News border surrounding the frame.
5 experts in this video
5 experts in this video
Related Content